View clinical trials related to Influenza, Human.
Filter by:Despite U.S. guidelines for influenza vaccination of all children starting at age 6 months, only about half of children are vaccinated annually leading to substantial influenza disease in children and spread of disease to adults. A major barrier is that families are not reminded about the need for their children to receive influenza vaccination. The investigators will evaluate the impact of patient reminder/recall (R/R) performed by state immunization information systems to improve influenza vaccination rates by using three clinical trials in two states. The investigators will assess effectiveness and cost-effectiveness of phone reminder/recall on improving influenza vaccination rates. The investigators will disseminate the state immunization information system based reminder/recall system to all states for use for both seasonal and pandemic influenza vaccinations with the goal of lowering influenza morbidity.
The investigators will compare two groups, an intervention group with a control group. Each employee of the University Hospital of Lausanne (CHUV) and the University Medical Policlinic of Lausanne (PMU) who will do his recruitment visit at the occupational medicine unit of the CHUV between 04/29/16 (end of previous influenza epidemic) and 31/10/16 (the day before the start of the next influenza vaccination campaign) and exert a function in regular contact with patients will be eligible. Depending on his employee number (assigned by the human resources administration, independent of any parameter), he will be placed in the intervention group G1 (odd number) or in the control group G2 (even number). The information concerning the distribution of these two groups will be noted in the computerized medical records of the employee at the occupational medicine unit (Medipho4D software, secured database). Thereafter, the employee will be received by the nurse of the he occupational medicine unit for a recruitment visit according to the usual process. The nurse will perform the study intervention in addition to the usual procedure if it is stipulated ''intervention group'' on the employee's record in the database or only perform the usual steps if it is stipulated ''control group''. At the beginning of the next influenza vaccination campaign (mid-November 2016), employees in the intervention group will receive a letter reminding then about the intervention given during the recruitment visit and inviting them to get vaccinated. During the next influenza vaccination campaign (11.01.16) and until the end of the influenza epidemic that will follow (April 2017), each employee will have the opportunity to be vaccinated at the different vaccination stalls set up by the occupational medicine unit. For each employee vaccinated, the date of vaccination and vaccine name is entered in the electronic medical records of the occupational medicine unit (Medipho4D software) by a nurse or a secretary of the unit. At the end of the human influenza epidemic (April 2017), the data will be extracted from the database (Medipho4D software) and anonymized by an individual not implicated in the study. Data from two groups will be analyzed and compared to assess whether the intervention conducted among newly hired employees promotes influenza vaccination.
A study to determine the infectious titre of an Influenza A (H1N1) (A/New Caledonia/20/99) virus for use in other Influenza challenge studies for the development of Influenza vaccines, antiviral agents and to better understand the host response to Influenza infection.
This is a global, multi-center, observational registry of participants with suspected or confirmed infection with avian influenza A H5N1. Data are collected through retrospective abstraction, from detailed case reports that may be published and available in the public domain, or as incident cases received directly from the treating physician or other medical personnel.
This prospective annual release study is designed to evaluate the safety of 1 new influenza virus vaccine strain to be included in FluMist Quadrivalent for the 2016-2017 influenza season
The purpose of this study is to test the effectiveness of brief face-to-face patient education in increasing uptake of influenza vaccine among Chinese elderly in the community.
An open label, non-comparative bridging study to evaluate the safety of GCFLU® (seasonal influenza vaccine) administered intramuscularly in healthy Vietnamese volunteer aged from 3 years old
Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by sudden fever, headache, muscle pain, cough, sore throat, nasal congestion and general malaise. The main transmission of influenza is through those highly contagious aerosol droplets containing influenza virus passed from infected people to susceptible population. Each year in the fall and winter infection of influenza is widespread in various age groups, with high incidence rate. Although influenza is generally a self-limiting disease, but in children, the elderly (especially those above 65 years old and those with chronic heart, lung, kidney, liver, blood or metabolic diseases such as diabetes or other certain diseases) and those with poor immunity function, influenza can easily lead to serious flu complications such as pneumonia, resulting in severe increase of morbidity and mortality. In order to evaluate safety and immunogenicity of a quadrivalent influenza vaccine produced by Jiangsu Jindike Biotechnology Co., Ltd. a phase III clinical trial is planned to conduct in healthy Chinese subjects aged 3 years and older.
This study evaluates the safety of Quadrivalent Influenza Virus Vaccine in Healthy People Aged years 3 to 60.40 Subjects will be equally divided into 2 groups,including 3-17 years old and 18-60 years old.Adult group first receive one dose of Quadrivalent Influenza Virus Vaccine.Then minors group also receive one dose of Quadrivalent Influenza Virus Vaccine after 7 days.
Haemophilus influenza type b (Hib) remains a serious global health threat associated with high mortality and morbidity in young children. In China, The overall impact of Hib-related infections and the extent of coverage of Hib conjugate vaccines are unclear.Generally, vaccination has been considered the most effective way to prevent infection against Hib.In order to evaluate safety and immunogenicity of a haemophilus influenzae type b (Hib) conjugate vaccine developped by Chengdu Olymvax Biopharmaceuticals Inc. a phase III clinical trial is planned to conduct in healthy infants and children in China.